Injectable drug CDMO Vetter has been recognised as CDMO of the year in the "Finished Dose" category of the 2026 CDMO Leadership Awards.
The award honours the company for exhibiting valued characteristics as a reliable and experienced partner, reaffirming its commitment to offering quality and technical know-how to its customers.
The company states that this acknowledgement highlights its strategic role as a trusted partner in the development and manufacturing of injectable drugs.
Given the increasing complexity of biologics and their handling processes, the pharmaceutical service provider continues to invest in technology, capacity and quality systems to meet the evolving needs of global customers.
Recent strategic investments in Europe and the United States are strengthening the company's global presence, including a planned capacity expansion of around €2bn through 2035.
"We are committed to supporting our customers every day and this award recognises our ongoing efforts to provide the best customer service experience possible," shared Lars Hahn, Vetter's Senior Vice President Global Sales Organisation.
It underscores our focus on operational excellence, reliability and innovation, as well as the devoted hard work of our 7300 employees to deliver life-enhancing or even life-saving medication to patients around the world.
The 15th Annual CDMO Leadership Awards, presented by Outsourced Pharma and Life Science Connect, were announced during DCAT Week in New York on March 25, 2026.
Award recipients are determined by independent research from the Tufts Center for the Study of Drug Development, using real-world outsourcing data and evaluations from biopharma companies.
CDMOs must meet specific qualifications and receive a minimum number of positive reviews to be eligible.
In 2026, excellence distinctions were awarded in five categories: Biologics, Cell and Gene Therapy, Small Molecule API, Finished Dose and Fill-Finish. The programme is recognised as a prestigious benchmark for excellence in the life sciences sector.
"The CDMO Leadership Awards represent something more meaningful than recognition," said Louis Garguilo, Chief Editor of Outsourced Pharma.
They reflect direct feedback from sponsors and the real-world experiences of companies navigating today's development and manufacturing landscape. This year's finalists and winners have demonstrated a consistent ability to deliver, adapt and operate as trusted partners.